Market Open logo. (Source: Stockhouse. Edited with Google Gemini)

The TSX is up 0.57%, while the TSX Venture Index is up 1.36%, as Canadian markets rise alongside a global tech rebound driven by bargain‑hunting and optimism surrounding Nvidia’s earnings later today.

U.S. markets opened stronger, with the S&P 500 up 0.43%, the Dow up 0.44%, and the Nasdaq higher by 0.40% as traders digested upbeat pre‑market sentiment tied to Meta and AMD’s 6‑gigawatt GPU announcement. The FTSE 100 gained 0.64% on broad‑based strength in financials and industrials.

Commodities are mixed. Gold rose nearly 0.8% after tariff uncertainty lifted safe‑haven demand, though oil slipped slightly following a multi‑day climb. Natural gas ticked higher, and copper gained just over 1%. Bitcoin surged nearly 3.8% in Canadian‑dollar terms after briefly dropping during Trump’s tariff speech before buyers stepped in. Markets continue watching inflation signals, U.S.–China tariff developments, and signs of rotation in global tech leadership.

Market numbers

TSX: Up (+0.57%), 33,970.38

TSXV: Up (+1.36%), 1,065.30

DOW: Up (+0.44%), 49,370.2

NASDAQ: Up (+0.40%), 25,095.1

FTSE 100: Up (+0.64%), 10,775.70

In the headlines

  • Lucid shares fall despite revenue beat: Lucid Group (NDAQ:LCID) — the U.S. luxury EV manufacturer known for its high‑performance Air sedan — saw its stock drop 5% despite reporting stronger‑than‑expected revenue and a positive delivery outlook. Investors focused on continued cash burn and production challenges.
  • BMO posts higher Q1 profit: Bank of Montreal (TSX:BMO) — one of Canada’s Big Five banks with major commercial and retail operations across North America — reported first‑quarter profit of $2.49 billion, up from $2.14 billion a year ago. Results were supported by stronger loan growth and stable credit performance.
  • GSK to acquire 35Pharma for $950M: GSK (NYSE:GSK) — the global pharmaceutical company behind numerous respiratory, vaccine, and specialty‑care treatments — agreed to acquire Montreal‑based 35Pharma for $950 million. The Canadian biotech is developing a novel therapy for pulmonary hypertension.

Currencies

USD: Up (+0.01%), $0.7298

GBP: Down (‑0.18%), $0.5399

EUR: Down (‑0.20%), $0.61989

JPY: Up (+0.53%), ¥114.410

AUD: Down (‑0.49%), $1.0289

Bitcoin (BTC/CAD): Up (+3.78%), 91,210.5

(Conversion to C$1)

Commodities

Copper: Up (+1.02%), 6.01872

Gold: Up (+0.79%), 5,184.40

WTI: Down (‑0.71%), 65.95

Natural Gas: Up (+1.41%), 2.885

To stay up-to-date on all of your market news head to Stockhouse.com.

Join the discussion: Find out what everybody’s saying about Lucid, BMO, and GSK for February 25th, 2026, on Stockhouse’s stock forums and message boards.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.


More From The Market Online

@ the Bell: TSX reaches new peak

Canada’s top stock index reached a new all‑time high on Wednesday, boosted by stronger precious metal...
The Market Online Video

Markets in Motion: Energy sector strength builds on fund inflows

Bruce Campbell examines energy sector leadership, relative rotation strength, and accelerating fund inflows into XLE and TSX energy stocks.

Loblaw stock falls after reporting higher revenue and earnings in Q4 2025

Loblaw (TSX:L) reported strong Q4 results, with comparable 12 week revenue up 3.5 per cent, higher customer traffic.

FDA grants full approval to Pfizer’s colorectal cancer treatment

The FDA granted full approval to Pfizer’s (NYSE:PFE) BRAFTOVI + cetuximab + fluorouracil based chemotherapy for adults.